We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+15.55%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$1.22B
AUM Growth
+$106M
Cap. Flow
+$6.46M
Cap. Flow %
0.53%
Top 10 Hldgs %
47.36%
Holding
68
New
14
Increased
14
Reduced
24
Closed
13

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$40.8M
2
ABBV icon
AbbVie
ABBV
+$33.3M
3
HCA icon
HCA Healthcare
HCA
+$31.2M
4
CI icon
Cigna
CI
+$27.4M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$25.7M

Top Sells

Rank Stock Value
1
ENDP
Endo International plc
ENDP
+$50.3M
2
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$41.9M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$21.6M
4
TVTY
Tivity Health, Inc. Common Stock
TVTY
+$21.2M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$20.6M

Sector Composition

Rank Sector Weight
1 Healthcare 85.69%
2 Financials 2.76%
3 Communication Services 1.41%
4 Technology 1.32%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GWPH
26
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$17.9M 1.47%
146,027
+26,913
+23% +$3.05M
INCY icon
27
Incyte
INCY
$23.3B
$17.2M 1.41%
+164,995
New +$17.1M
MODN
28
DELISTED
MODEL N, INC.
MODN
$17.2M 1.41%
1,443,278
-18,400
-1% -$218K
OXFD
29
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$16.8M 1.38%
1,212,892
-202,590
-14% -$2.74M
CSLT
30
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$16.2M 1.32%
1,984,631
-351,867
-15% -$2.93M
ZSPH
31
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$15.9M 1.3%
302,988
-102,700
-25% -$5.06M
CASC
32
DELISTED
Cascadian Therapeutics, Inc.
CASC
$15.6M 1.28%
+694,146
New +$11M
CIVI
33
DELISTED
Civitas Solutions, Inc.
CIVI
$14M 1.15%
657,693
-221,792
-25% -$4.58M
FATE icon
34
Fate Therapeutics
FATE
$294M
$13M 1.06%
+2,007,446
New +$12M
DVA icon
35
DaVita
DVA
$15B
$11.1M 0.91%
140,191
-125,667
-47% -$10.3M
BPMC
36
DELISTED
Blueprint Medicines
BPMC
$9.67M 0.79%
+378,235
New +$10.8M
ADVM
37
DELISTED
Adverum Biotechnologies
ADVM
$8.72M 0.72%
53,728
+11,615
+28% +$3.92M
PRQR icon
38
ProQR Therapeutics
PRQR
$253M
$8.61M 0.71%
516,690
-234,481
-31% -$4.42M
GNCA
39
DELISTED
Genocea Biosciences, Inc.
GNCA
$8.56M 0.7%
77,940
-21,673
-22% -$2.01M
LAB icon
40
Standard BioTools
LAB
$343M
$8.43M 0.69%
348,237
-214,200
-38% -$6.76M
CERS icon
41
Cerus
CERS
$575M
$8.32M 0.68%
1,603,427
-44,300
-3% -$210K
TRIV
42
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
$7.83M 0.64%
1,464,563
-124,060
-8% -$880K
PTLA
43
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$6.96M 0.57%
+152,700
New +$6.14M
RARE icon
44
Ultragenyx Pharmaceutical
RARE
$2.66B
$6.9M 0.57%
67,425
-265,175
-80% -$20.6M
BLCM
45
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$5.07M 0.42%
23,812
-20,710
-47% -$5.08M
CCXI
46
DELISTED
ChemoCentryx, Inc.
CCXI
$3.92M 0.32%
476,293
+458,793
+2,622% +$3.64M
CARM
47
DELISTED
Carisma Therapeutics
CARM
$3.56M 0.29%
63,063
+51,063
+426% +$7.21M
FLXN
48
DELISTED
Flexion Therapeutics, Inc.
FLXN
$3.12M 0.26%
142,483
-47,141
-25% -$951K
SIOX
49
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$3.06M 0.25%
+18,750
New +$3.18M
NVTA
50
DELISTED
Invitae Corporation
NVTA
$2.56M 0.21%
181,224
-603,907
-77% -$8.59M
1
2
3

Similar funds

KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Redmile Group's Q2 2015 Portfolio in Review

As of Q2 2015, Redmile Group held 68 positions worth $1.22B, up 9.6% from $1.11B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Redmile Group's Q2 2015 filing shows 14 new, 14 increased, 24 reduced and 13 closed positions. Its largest new stake was Allergan plc: 136,818 shares worth $41.5M. The largest sale was Endo International plc, an estimated $50.3M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 81% a quarter earlier, followed by Financials and Communication Services.

  • Redmile Group's largest Q2 2015 buy was Allergan plc: 136,818 shares worth $41.5M.
  • Redmile Group added most to Bausch Health in Q2 2015, an estimated $25.7M increase.
  • Redmile Group's biggest Q2 2015 reduction was Seagen Inc. Common Stock, cutting an estimated $21.6M.
  • Redmile Group fully exited Endo International plc in Q2 2015, selling an estimated $50.3M.
  • Redmile Group's ten largest holdings make up 47% of its $1.22B portfolio in Q2 2015.
  • Redmile Group opened 14 new positions and closed 13 in Q2 2015.
  • Redmile Group's portfolio value rose 9.6% quarter-over-quarter to $1.22B.

Based on Redmile Group's 13F filing for Q2 2015, filed 14 Aug 2015.